Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00496457
Recruitment Status : Completed
First Posted : July 4, 2007
Last Update Posted : November 22, 2016
Ergomed GmbH
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
The purpose of this study is to assess the efficacy and safety of TRO19622 administered PO daily for 6 weeks compared to placebo administered PO daily in patients with painful peripheral diabetic neuropathy.

Condition or disease Intervention/treatment Phase
Diabetic Neuropathy Drug: Experimental Drug: Placebo comparator Phase 2

Detailed Description:

Diabetic peripheral neuropathic pain (DPNP) affects approximately 11% of patients with diabetic peripheral neuropathy (DPN). Diabetic neuropathy as the underlying disease is the most common long-term complication of diabetes mellitus estimated to be experienced by a majority of patients at least in a mild manner.

Many patients with (DPNP) do not respond adequately to any individual treatment option. None of the various treatments used can be considered a cure. As a result, although a variety of drugs are available for the treatment of diabetic neuropathic pain, there is a strong need to develop new drugs with greater efficacy and/or fewer adverse effects.

The primary objective of the study is to compare the effect of TRO19622 versus placebo on the 24h neuropathic pain scores during the last 7 days of the 6-week treatment period.

Secondary objectives are to compare the efficacy on neuropathic pain, impact on emotional functioning, safety profile, pain time course, and response rate of TRO19622 versus placebo. Additionally, the pharmacokinetics of TRO19622 will be assessed.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 159 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Multicenter Study With 500 mg QD of TRO19622 Versus Placebo in Patients With Painful Peripheral Diabetic Neuropathy
Study Start Date : May 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Drug: Experimental
Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks

Placebo Comparator: 2 Drug: Placebo comparator
4 Capsules of PBO per day before noon meal

Primary Outcome Measures :
  1. Effect of TRO19622 versus Placebo on the mean 24h neuropathic pain score on the Likert numerical rating scale. [ Time Frame: During the last 7 days of the 6-week treatment period ]

Secondary Outcome Measures :
  1. 24h Pain time course [ Time Frame: Duration of study (within 11weeks after screening) ]
  2. Analysis for treatment effects: SF-MPQ, SF-BPI, SF36, POMS, Global Impression of Change (Patient / Investigator) [ Time Frame: Within 6 weeks of treatment ]
  3. Adverse events [ Time Frame: During the course of the study. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be a male >18 years or a post-menopausal female (>60 years of age and at least 1 year of amenorrhea).
  • Have painful diabetic neuropathy of >6 months duration and are either pain treatment naive or have important side effects or inadequate relief from their current pain medication.
  • Be on current pain medication (prescribed analgesics), stable for at least 3 months before study entry (± 25% dosage of basic pain medication, top-up rescue medication allowed), or pain treatment naive.
  • Have stable diabetes, defined as HbA1c <10%, no changes in medication in the previous 3 months, and no new symptoms associated with diabetes in the previous 3 months.
  • Have scored >2 points on the Michigan Neuropathy Screening Instrument (MNSI), part B-physical assessment by health professional.
  • Have an ECG without any clinically significant abnormality.

The following inclusion criteria should be ascertained at the baseline visit:

  • Have measurable pain perception (previous 24h) on the Likert numerical rating scale with a mean≥4.0 points calculated from at least 4 daily measurements over the 7 days immediately prior to the Baseline Visit.
  • Have stopped current pain medication at least 14 days prior to the Baseline Visit (except rescue medication).

Exclusion Criteria:

  • Be pregnant female, lactating female, or female of child bearing potential (≤60 years of age).
  • Have a documented neuropathy of any cause other than those mentioned in the inclusion criteria which might interfere with the assessment of the severity of pain (eg, including, but not limited to, alcoholic, uremic, B12, TSH, chemotherapy, HIV, post surgical, or post-traumatic neuropathy).
  • Have other neurological diseases that may produce weakness, sensory loss, or autonomic symptoms, or laboratory test abnormality.
  • Have been on pain treatment with strong opioids, more than 4 different drug regimens in the previous year, or a current combination of more than 2 drugs.
  • Have a current medication of lipid lowering agents other than statins.
  • Have a body mass index (BMI) >40 kg/m2 (obesity grade III).
  • Had any surgery within the previous 2 months.
  • Have concurrent serious neurological disease (eg, dementia, multiple sclerosis, or any other disease that would impact the ability of the patient to provide consent for study participation).
  • Have a recent history (within the previous 6 months) or current evidence of alcohol or drug abuse.
  • Have concurrent unstable disease involving any system (eg, advanced carcinoma, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency i.e.≥ NYHA functional classification class 2, anginal symptoms, current symptoms of CAD, renal impairment, or any other condition that in the opinion of the Investigator would make the patient unsuitable for study participation).
  • Participated in any other investigational drug or therapy study within the previous 3 months.
  • Changed or interrupted current well-tolerated medication during the previous 3 months.
  • Lack of ability or willingness to give informed consent.
  • Be possibly dependent on the Investigator or the Sponsor (eg, including, but not limited to, affiliated employee).
  • Have hemostasis disorders or a current treatment of anticoagulants.
  • Have non-adequate renal and/or hepatic function as follows:

    • Renal - Blood creatinine >1.5X upper limit of normal (ULN)
    • Hepatic - Liver enzymes (ALT and AST) >2 X ULN
  • Have a known history of or current cardiac dysrhythmias and / or a known history of or current cardiovascular disease including myocardial infarction except patients with well controlled hypertension only.
  • Are not able to comply with regard to the known contraindications, warnings and precautions, drug-interactions and dosing recommendations of paracetamol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00496457

Univerity Hospital OSIJEK, Department for Diabetes and Endocrinology, J.Huttlera 4
Osijek, Croatia, 31 000
Genaral Hospital "Josip Bencevic", Internal Medicine Department-Unit for Diabetes, Andrije Stampara 42
Slavonski Brod, Croatia, 35 000
General Hospital Varazdin, Internal Medicine Department-Unit for Diabetes, Ivana Mestrovica bb
Varazdin, Croatia, 42 000
University Hospital "Dubrava", University Department for Internal Medicine, Institut for Diabetes, Endocrinology and Metabolic diseases, Avenija Gojka Suska 6
Zagreb, Croatia, 10 000
Diabetes Zentrum Mergentheim - Theodor-Klotzbücher-Straße 12
Bad Mergentheim, Germany, 97980
Diabetologische Schwerpunktpraxis - Wilhelminenstr. 22
Dinslaken-Bruch, Germany, 46537
Deutsches Diabetes Center, Institut für Klinische Diabetologie, Leibniz-Zentrum an der Heinrich-Heine Universität - Auf'm Hennekamp 65
Duesseldorf, Germany, 40225
Klinikum Region Hannover GmbH - Klinikum Hannover Nordstadt - Diabetes Schwerpunktklinik -Medizinische Klinik - Haltenhoffstr. 41
Hannover, Germany, 30167
Universitätsklinikum Heidelberg - Abteilung Innere Medizin I und klinische Chemie - Im Neuenheimer Feld 410
Heidelberg, Germany, 69120
Pro scientia med - Osterweide 10
Lübeck, Germany, 23562
IKFE GmbH - Institut für klinische Forschung und Entwicklung - Parcusstr. 8
Mainz, Germany, 55116
Diabetes Schwerpunktpraxis - Gesundheitszentrum Potsdam GmbH - Hebbelstr. 1A
Potsdam, Germany, 14467
Diabetes Schwerpunktpraxis - Gesundheitszentrum Potsdam GmbH, Hebbelstr. 1A
Potsdam, Germany, 14467
Sophien- und Hufeland-Klinikum gGmbH - Klinik für Neurologie und Klinische Neurophysiologie - Henry-van-de-Velde-Str. 2
Weimar, Germany, 99425
Daugavpils Regional Hospital - Vasarnicu street 20
Daugavpils, Latvia, LV-5420
Zemgale's Diabetes Centre SIA - Zemgales boulevard 15
Jelgava, Latvia, LV-3000
Doctor's Practice in Endocrinology - Meža prospekts 9, 2nd floor, 41.kabinets
Ogre, Latvia, LV-5001
Clinical Research Centre "Riga" - Katrinas dambis 16
Riga, Latvia, LV-1045
Talsu Hospital - Rugena street 7
Talsi, Latvia, LV-3201
NZOZ Specjalistyczny Ośrodek, Internistyczno-Diabetologiczny, ul Zamenhofa 10/20
Białystok, Poland, 15-435
Centrum Neurologii Klinicznej - Ul. Dwernickiego 8
Kraków, Poland, 31-530
NZOZ Special-Med. Ul. Weteranów 46
Lublin, Poland, 20-044
NZOZ MEDICA, ul. Jutrzenki 4
Lublin, Poland, 20-538
NZOZ Beta-Med., Plac Wolności 17
Rzeszów, Poland, 35-073
Adamiec Rajmund Gabinet Lekarski, ul. Żelazna 34
Wrocław, Poland, 53-428
Centre of Neurology, Clinical Hospital Centre "Dr Dragisa Misovic"
Belgrade, Serbia, 11000
Clinic for Neurology and Psychiatry, Clinical Hospital Centre "Zvezdara"
Belgrade, Serbia, 11000
Institute for Endocrinology, Clinical Centre Serbia
Belgrade, Serbia, 11000
Neurology Clinic, Military Medical Academy
Belgrade, Serbia, 11000
Neurology Department, Clinical Hospital Zemun
Belgrade, Serbia, 11000
Center for Neurology, Clinical Centre "Kragujevac"
Kragujevac, Serbia, 34000
Sponsors and Collaborators
Hoffmann-La Roche
Ergomed GmbH
Study Chair: Jean-Louis Abitbol, MD Trophos, Parc Scientifique de Luminy - Case 931, Luminy Biotech Enterprises, 13288 Marseille Cedex9 - France
Principal Investigator: Dan Ziegler, MD German Diabetes Center, German Diabetes Clinic, Leibniz Institute at the Heinrich-Heine University, Auf ´m Hennekamp 65, 40225 Dusseldorf, Germany

Responsible Party: Hoffmann-La Roche Identifier: NCT00496457     History of Changes
Other Study ID Numbers: WN29860
EudraCT Number: 2006-004545-42
TRO19622 CLEQ 1104-1 ( Other Identifier: trophos id )
First Posted: July 4, 2007    Key Record Dates
Last Update Posted: November 22, 2016
Last Verified: November 2016

Keywords provided by Hoffmann-La Roche:
Diabetic Neuropathy
Painful Peripheral Diabetic Neuropathy

Additional relevant MeSH terms:
Peripheral Nervous System Diseases
Diabetic Neuropathies
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases